

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| None were identified. |

- | |
|---|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| <p>The company raised the issue that they considered the replacement of the EoL modifier (which applied in the original appraisal) with the new severity modifiers might disadvantage patients approaching EoL.</p> <p>The company also stated that given the review appraisals for pomalidomide with dexamethasone and daratumumab were concluded before the new NICE manual was published, so were not subjected to the new methods, it considered it to be inequitable that isatuximab with pom/dex is assessed under a different framework.</p> <p>The committee did not consider this to be an equality issue. The application of the new methods applies to all ongoing new topics equally many of which are being compared with treatments recommended using the previous methods framework.</p> |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

The draft guidance states that the committee did not identify any equality issues.

Approved by Associate Director (name):Richard Diaz.....

Date: 2 Feb 2024